CBLC polyclonal antibody
- Known as:
- CBLC pab (anti-)
- Catalog number:
- PAB9985
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- CBLC polyclonal antibody
Related genes to: CBLC polyclonal antibody
- Gene:
- CBLC NIH gene
- Name:
- Cbl proto-oncogene C
- Previous symbol:
- -
- Synonyms:
- CBL-3, CBL-SL, RNF57
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-25
- Date modifiied:
- 2019-04-23
Related products to: CBLC polyclonal antibody
Related articles to: CBLC polyclonal antibody
- This guideline summarizes diagnostic and therapeutic approaches based on a systematic literature review and evidence evaluation using the GRADE methodology. Given the limited high-quality data, expert consensus was additionally obtained through a modified Delphi process. Remethylation disorders are rare inherited conditions that disrupt the methionine-homocysteine cycle and consecutively impair essential methylation dependent metabolic pathways. Remethylation disorders are caused by defects in the cobalamin or folate metabolism. The disorders typically result in elevated homocysteine and often low methionine; combined cobalamin-related defects also affect mitochondrial methylmalonic acid clearance. The cblC-MMACHC defect is the most common cobalamin-related remethylation disorder. Early-onset patients usually present with severe neurological and eye symptoms. Late-onset cases show variable symptoms (e.g., psychiatric, renal, thromboembolic events). Plasma total homocysteine, methionine, methylmalonic acid, serum vitamin B12 (and folates) should be assessed in suspected cases. Early detection through newborn screening is associated with improved clinical outcomes. Betaine as first-line therapy for methylenetetrahydrofolate reductase deficiency and parenteral hydroxocobalamin for cobalamin-related defects have reduced mortality and morbidity. Total homocysteine, methionine (and methylmalonic acid) should be kept as close to normal values as achievable. Emerging evidence suggests that early use of high-dose hydroxocobalamin (> 0.35 mg/kg/day) may improve neurocognitive impairment and may ameliorate eye disease in severe cobalamin-related defects. A major limitation in current practice is the lack of availability of high concentration hydroxocobalamin formulations for parenteral administration. - Source: PubMed
Olivieri GiorgiaBordugo AndreaBurnyte BiruteCostetti AlessandroCouce Maria-LuzDiogo LuisaFeillet FrancoisFroese D SeanGreco BenedettaGueant Jean-LouisHannibal LucianaHörster FriederikeKožich ViktorLa Marca GiancarloManoli IriniMochel FannyOrazi LorenzoPérez BelénSchiff ManuelSchwahn Bernd CSchwartz IdaStepien Karolina MSykut-Cegielska JolantaTangeraas TrineZetterström Rolf HDionisi-Vici CarloHuemer Martina - E3 ubiquitin ligases are critical regulators of cell signaling and proteostasis that play a critical role in many diseases, including cancer. We aimed to investigate how E3 ubiquitin-protein ligase Casitas B-lineage lymphoma proto-oncogene C (CBLC) affects the development of endometrial cancer. Single-cell sequencing and bulk transcriptome analysis revealed a significant upregulation of CBLC expression in endometrial cancer cells. Functionally, CBLC accelerated the proliferation, migration, and invasiveness of endometrial cancer cells but suppressed their apoptosis. Mechanistically, CBLC ubiquitinated tRNA (guanine-N(7)-)-methyltransferase (METTL1), making it more stable and resistant to proteasomal degradation. METTL1 upregulation enhanced the N7-methylguanosine (m7G) modification of the estrogen-related receptor alpha (ESRRA) mRNA, enhancing its stability. ESRRA, in turn, mediated the pro-tumorigenic properties of CBLC. In conclusion, our study revealed that CBLC promotes the progression of endometrial cancer by orchestrating post-transcriptional and post-translational signaling cascades that stabilize METTL1 via ubiquitination and facilitate ESRRA m7G modification. These processes represent promising therapeutic targets for endometrial cancer. - Source: PubMed
Publication date: 2026/05/30
Peng JingweiZhang LinlinWang RuWang XiangyuLiu Ming - Gastric cancer (GC) is a leading cause of cancer-related mortality globally, and elucidating the molecular drivers of its progression is essential for therapy development. The E3 ubiquitin ligase CBLC has been implicated in tumorigenesis, yet its role in GC remains undefined. - Source: PubMed
Publication date: 2026/05/12
Pan JingjingXiao Yiwen - This study aims to screen and validate the differentially expressed gene synaptophysin 1 (SYT1), which plays a key regulatory role in prostate cancer, explore its function and potential regulatory mechanisms, and clarify its biological role and molecular mechanisms in the malignant progression of prostate cancer. - Source: PubMed
Publication date: 2026/05/12
Tong JianyongHu LiangLiu QuanqiTian Daxue - Cobalamin C (cblC) deficiency is one of the most common congenital vitamin B12 metabolic abnormalities, and may cause severe neurologic symptoms, gastrointestinal and nephritic symptoms. - Source: PubMed
Cui XuxiaZhong YajingYin Chongjuan